Last mentioned: Mar 14, 2026
Offering Upsized
The company prices an upsized $550M offering due to strong institutional interest.
ARK Invest Trade
Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
Debt Offering Announced
CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.
ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
This page surfaces every story mentioning Vertex Pharmaceuticals across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Vertex Pharmaceuticals was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |